Citation only
via Europe PMC
Gut-brain immune dysregulation in Parkinson's disease: a hypothesis-forming narrative review of trained immunity.
Tang M, Li J, Zhang C, Tu R, Wang S.
Frontiers in aging neuroscience · 2026
Loss of proteostasis
Dysbiosis
Cellular senescence
Altered intercellular communication
Chronic inflammation
Partial reprogramming (OSK)
Human
Review
Abstract
Parkinson's disease (PD) is increasingly understood as a multisystem disorder in which gastrointestinal dysfunction, immune remodeling, protein aggregation, and central neurodegeneration interact across the disease course. Although gut microbiota alterations are repeatedly reported in PD, taxonomic differences alone do not explain how peripheral ecological signals acquire neurological relevance. This review therefore focuses on immune translation: the processes through which dysbiosis, microbial metabolites, intestinal barrier stress, and mucosal inflammation may reshape peripheral immunity and lower the threshold for central neuroinflammatory responses. Particular attention is given to trained immunity as a mechanistic framework that may connect repeated low-grade gut-derived stimulation with persistent innate immune reprogramming. Direct evidence that trained immunity drives PD remains limited; the concept is presented as a testable bridge rather than an established causal pathway. We integrate this framework with age-related immunosenescence and inflammaging(definition), enteric nervous system vulnerability, vagal communication, alpha-synuclein pathology, blood-brain barrier signaling, and microglial priming. Human microbiome studies, Parkinsonian animal models, LPS-based innate immune-memory paradigms, and emerging intervention trials are considered according to their evidentiary level and major confounders, including constipation, diet, medication exposure, geography, and disease stage. The resulting model accommodates body-first, brain-first, and mixed trajectories rather than assigning a universal gut origin to PD. Therapeutically, the evidence supports a shift from nonspecific microbiome normalization toward mechanism-matched strategies that combine ecological, immune, metabolic, and clinical biomarkers. Longitudinal prodromal cohorts and integrated multi-omics with immune phenotyping will be essential to determine whether gut-brain immune signatures identify causal pathways, progression markers, or treatment-responsive subgroups.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fnagi.2026.1973833
- Canonical
- link ↗
- Fetched
- 2026-10-17 MST
Cite this
APA
M, T., J, L., C, Z., R, T., & S., W. (2026). Gut-brain immune dysregulation in Parkinson's disease: a hypothesis-forming narrative review of trained immunity. <em>Frontiers in aging neuroscience</em>. https://doi.org/10.3389/fnagi.2026.1973833
Vancouver
M T, J L, C Z, R T, S. W. Gut-brain immune dysregulation in Parkinson's disease: a hypothesis-forming narrative review of trained immunity. Frontiers in aging neuroscience. 2026. doi:10.3389/fnagi.2026.1973833.
BibTeX
@article{tang2026Gutbra,
title = {Gut-brain immune dysregulation in Parkinson's disease: a hypothesis-forming narrative review of trained immunity.},
author = {Tang M and Li J and Zhang C and Tu R and Wang S.},
journal = {Frontiers in aging neuroscience},
year = {2026},
doi = {10.3389/fnagi.2026.1973833},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in aging neuroscience
Open access · OA
Gut-brain immune dysregulation in Parkinson’s disease: a hypothesis-forming narrative review of trained immunity
Cell insight 2026
Open access · OA
Remodeling of innate antiviral immunity in aging
Journal of clinical medicine 2026
Open access · OA
The Gut-Eye Axis and Microbiome in Ophthalmic Diseases: A Narrative Review.
Elsevier eBooks 2026
Citation only
DNA damage, aging concept: Feasibility and significance
Ageing Research Reviews 2020
Citation only
TIP60 in aging and neurodegeneration
Biomedical Research and Therapy 2026
Open access · CC-BY